MACROGENICS, INC. Inventory
MACROGENICS, INC. (MGNX) had Inventory of $9.50 million as of 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Balance Sheet › Assets › Assets, Current › Inventory, Net
us-gaap:InventoryNet · last filed 2026-05-13
- 2026-03-31: Inventory, Net $9.50M.
- 2025-12-31: Inventory, Net $7.91M.
- 2025-09-30: Inventory, Net $8.75M.
- 2025-06-30: Inventory, Net $9.28M.
| Period end | Inventory, Net |
|---|---|
| 2026-03-31 | $9.50M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $7.91M 10-Q · filed 2026-05-13 |
| 2025-09-30 | $8.75M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $9.28M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $9.43M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-09 |
| 2024-09-30 | $3.24M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $1.11M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $1.25M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $1.22M 10-K · filed 2025-03-20 |
| 2023-09-30 | $1.07M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $1.44M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $1.41M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $1.45M 10-K · filed 2024-03-07 |
| 2022-09-30 | $1.09M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $2.95M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $4.60M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $4.39M 10-K · filed 2023-03-15 |
| 2021-09-30 | $3.98M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $6.48M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $6.17M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |